on BIOMERIEUX (EPA:BIM)
BioMérieux Gains IVDR Class D CE Marking for Syndromic Respiratory Panels
bioMérieux has announced that its BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel have obtained IVDR Class D CE Marking. This is the highest risk classification under the European Union's In Vitro Diagnostic Regulation. These panels are the first to include MERS-CoV, indicating a significant regulatory milestone for bioMérieux.
The panels offer multiplex testing, detecting multiple pathogens from a single sample in under an hour. Including MERS-CoV in these tests aids in rapid identification or exclusion of this pathogen alongside other respiratory agents, assisting clinicians in making timely treatment decisions.
This certification emphasizes bioMérieux’s dedication to providing innovative diagnostic solutions. The certified panels will be available on the European market early next year.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOMERIEUX news